1. Introduction {#sec1-vaccines-08-00124}
===============

Pregnancy induces immune modulation that renders women more susceptible to severe manifestations of infectious diseases, some of which can potentially be prevented by vaccination, e.g., influenza. In addition to protecting the mother, vaccination during pregnancy also serves as a vehicle to protect the unborn or newborn child via high-titer transplacental antibodies which can safeguard infants until active immunity through childhood vaccination has been established \[[@B1-vaccines-08-00124]\].

Scientific evidence supporting the effectiveness of certain inactivated vaccines in pregnancy is growing. Maternal immunization with tetanus, inactivated influenza and pertussis containing vaccines is currently recommended in many countries based on extensive data supporting their safety, and proven benefits for the mother--infant pair \[[@B1-vaccines-08-00124],[@B2-vaccines-08-00124],[@B3-vaccines-08-00124]\].

Live viral vaccines (LAV), on the other hand, can replicate in the host and are potentially capable of causing viremia \[[@B4-vaccines-08-00124],[@B5-vaccines-08-00124],[@B6-vaccines-08-00124]\], conveying the risk of transplacental transmission to the developing fetus with potential adverse consequences on pregnancy outcomes. Safety of vaccination during the first trimester is of particular concern. During this period, women are more likely to be inadvertently vaccinated in the context of mass campaigns, as they might not yet be aware of their pregnancies.

The theoretical risks associated with LAV have led to the exclusion of pregnant women from clinical trials, hindering the development of high-quality evidence regarding potential benefits and harms in this group. Despite the vast employment of LAV in diverse settings, current evidence comes mainly from observational studies and national teratology registries \[[@B7-vaccines-08-00124]\].

The extensive use of smallpox vaccine in the 20th century brought about dozens of reported cases of fetal vaccinia, resulting in stillbirth or neonatal death. The risk of fetal vaccinia has been estimated at one per 10,000 to 100,000 immunizations during pregnancy \[[@B8-vaccines-08-00124],[@B9-vaccines-08-00124]\].

With regards to rubella vaccine, there is evidence of vertical transmission and subclinical fetal infection, as demonstrated by immunoglobulin M (IgM) titers in cord blood of exposed infants \[[@B10-vaccines-08-00124],[@B11-vaccines-08-00124],[@B12-vaccines-08-00124]\], and more recently by molecular methods \[[@B13-vaccines-08-00124]\].

Oral poliovirus vaccine (OPV) has been widely used in mass immunization campaigns targeting children and adults, including pregnant women. Transplacental infection with wild-type poliovirus has been documented \[[@B14-vaccines-08-00124]\], and a fatal case of spinal cord damage after maternal immunization was described \[[@B15-vaccines-08-00124]\]. However, fetal infection with OPV has not been definitely proven. Similarly, yellow fever (YF) vaccine is capable of causing viremia but its potential for causing fetal infection is uncertain \[[@B16-vaccines-08-00124],[@B17-vaccines-08-00124]\].

Major health benefits may be lost if maternal immunization is withheld on the basis of unproven safety concerns, especially in the case of diseases that disproportionately affect pregnant women and their offspring, and in outbreak scenarios. In recent years, the epidemics of Ebola and Zika have led to an enhanced interest in the role of LAV in pregnant women and the ethical issues surrounding their exclusion in clinical trials in such scenarios \[[@B18-vaccines-08-00124]\]. Furthermore, it is important to improve our knowledge of the safety of vaccines that might be used in mass campaigns where pregnant women may be inadvertently vaccinated, in order to inform future research and health policy.

Given the increasing likelihood that LAV could be used to combat emerging infectious disease such as Ebola, Lassa and others, we aimed to assess the body of evidence evaluating the safety of maternal immunization with LAV, and to identify the main areas of uncertainty where new studies could be beneficial.

2. Materials and Methods {#sec2-vaccines-08-00124}
========================

For this systematic review and meta-analysis we searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Global Health, [ClinicalTrials.gov](ClinicalTrials.gov), as well as Open Grey and MedNar for published and unpublished studies from the inception of each database. The search strategy was constructed in collaboration with a medical librarian ([Table S1](#app1-vaccines-08-00124){ref-type="app"}). The reference list of all included articles was searched for additional studies. The initial search was conducted on June 2019 and updated on 20 November 2019.

Primary studies of experimental and epidemiological study designs were deemed eligible for inclusion if adverse pregnancy outcomes (i.e., miscarriage, stillbirth, neonatal death, prematurity, low birth-weight, birth defects and congenital infection) were assessed in mother-infant pairs exposed to immunization with one or more LAV during pregnancy or in the three months before conception, and compared to mother-infant dyads with no exposure during or immediately before gestation. Narrative reviews, case series, passive surveillance studies with no clear denominator, observational studies with no control group, and articles with unavailable full text were excluded from the review. No language or geographic restrictions were applied.

The search results from each database were exported to Mendeley 1.19.4 and deduplicated. Two reviewers (A.L. and D.B.) independently screened titles and abstracts, reviewed full texts of potentially relevant articles against inclusion criteria, and extracted data into a previously designed data collection form. Extracted data included study design, funding, country and setting, characteristics of the exposed and control groups, potential confounders, number of participants, vaccine(s) administered, trimester of pregnancy at vaccination, outcome definition and time points, number of events and sample size for all prespecified outcomes, crude and adjusted estimates of effect and variables included in adjusted analyses.

Included studies were independently evaluated by both reviewers using the ROBINS-I tool ("Risk Of Bias In Non-randomized Studies---of Interventions") \[[@B19-vaccines-08-00124]\]. The GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach was employed to assess overall quality of evidence for the prespecified outcomes. Any discrepancies were solved by discussion and consensus, consulting a third and fourth reviewer if necessary.

Data Analysis
-------------

A narrative synthesis was used to summarize the characteristics, results and internal validity of included studies, by vaccine. Meta-analyses were carried out using Review Manager software 5.3 (Cochrane Collaboration, Oxford, UK) for outcomes for which studies were deemed comparable. Pooled estimates of effect were obtained using the generic inverse-variance method under a random effects model, and presented as odds ratios (OR) and their 95% confidence intervals (CI). Fixed zero-cell correction was used for studies with no events in one or more groups. The degree of variability between studies was assessed using the I^2^ statistic and heterogeneity was evaluated according to the Cochrane Handbook guidelines.

Given the variety of vaccine types that we encountered and their potentially different effect on pregnancy outcomes, we decided to do subgroup analyses by vaccine type, which had not been pre-specified in the protocol. Sensitivity analyses were conducted excluding studies at critical risk of bias. Given the greater susceptibility of the embryo to potential harmful effects of vaccines, we also decided to perform sensitivity analyses for the association of vaccination in the first trimester of pregnancy with miscarriage and congenital anomalies.

In addition to the studies included in the meta-analyses according to prespecified criteria, cohorts with no comparison group were summarized to obtain further safety data, especially regarding rare outcomes. The risk of congenital rubella syndrome (CRS) was calculated from studies of rubella vaccination, including controlled and uncontrolled cohorts. The upper limit for the risk of CRS was based on two-tailed 95% CI from the Poisson distribution.

There was no funding source for this study. The study protocol was registered with PROSPERO, number CRD42019138360.

3. Results {#sec3-vaccines-08-00124}
==========

The search strategy identified 2831 articles following the removal of duplicates, of which 15 studies were included in the main body of this review: 12 cohorts (six retrospective, five prospective and one historically-controlled), two case-controls, and one secondary data analysis from clinical trials ([Figure 1](#vaccines-08-00124-f001){ref-type="fig"}).

An overview of the key characteristics of included studies is provided [Table 1](#vaccines-08-00124-t001){ref-type="table"}. All retrievable articles were published in English and focused on populations from high and middle income countries (see [Appendix A](#app2-vaccines-08-00124){ref-type="app"}). Sample size varies considerably, from a few dozens to over 9000 participants per group. Only one was industry-funded \[[@B20-vaccines-08-00124]\]. Included studies reported on outcomes after immunization with one of the following vaccines: smallpox (eight studies), rubella (three), OPV (two), YF (one), and dengue (one).

3.1. Meta-Analysis of Pregnancy Outcomes {#sec3dot1-vaccines-08-00124}
----------------------------------------

Meta-analysis was carried out for the outcomes of miscarriage, stillbirth, congenital anomalies, prematurity, and neonatal death (See [Table 2](#vaccines-08-00124-t002){ref-type="table"}). Data on congenital infection and LBW was considered inadequate for meta-analysis given the scarcity of studies reporting these outcomes, and the heterogeneity in the methods of outcome assessment for congenital infection.

### 3.1.1. Miscarriage {#sec3dot1dot1-vaccines-08-00124}

Four studies on smallpox vaccine, two on rubella, and one each on OPV, YF, and dengue vaccine reported on miscarriage. Meta-analysis showed no association between immunization and spontaneous abortion overall and for each type of vaccine (pooled OR: 0.98; 95% CI 0.87--1.10). No statistical heterogeneity was detected across studies (I^2^ = 0%) ([Figure 2](#vaccines-08-00124-f002){ref-type="fig"}a).

The analysis for exposure in the first trimester of pregnancy revealed a pooled OR of 2·66 (95% CI 0.73--9.64). However, the subgroup analysis showed a strong association between smallpox vaccination and miscarriage (OR 4.82, 95% CI 2.38--9.77, *p* \< 0·0001) as shown in [Figure 2](#vaccines-08-00124-f002){ref-type="fig"}b.

Quality of evidence was rated as very low, given a critical risk of selection bias ([Table S2](#app1-vaccines-08-00124){ref-type="app"}). When considering exposure to vaccination in the first trimester, downgrading was also granted for imprecision. Funnel plot revealed no evidence of publication bias ([Figure S1](#app1-vaccines-08-00124){ref-type="app"}).

### 3.1.2. Stillbirth {#sec3dot1dot2-vaccines-08-00124}

No association was found between vaccination and stillbirth (pooled OR: 1.04; 95% CI 0.74--1.48) in the pooled analysis of nine studies, including six on smallpox, and one each on rubella, OPV, and dengue vaccine ([Figure 3](#vaccines-08-00124-f003){ref-type="fig"}). There was moderate statistical heterogeneity between studies (I^2^ = 45%, *p* = 0.07) and quality of evidence was rated as very low due to serious risk of bias ([Table S3](#app1-vaccines-08-00124){ref-type="app"}). Funnel plot revealed no evidence of publication bias ([Figure S2](#app1-vaccines-08-00124){ref-type="app"}).

### 3.1.3. Congenital Anomalies {#sec3dot1dot3-vaccines-08-00124}

Eight studies on smallpox vaccine, two on rubella, and two on OPV contributed data for the meta-analysis of congenital anomalies, revealing no evidence of an association with maternal immunization (pooled OR: 1.09; 95% CI 0.98--1.21); this also held true when considering only pregnancies exposed to vaccination in the first trimester (pooled OR: 1.22; 95% CI 0.87--1.72), as depicted in [Figure 4](#vaccines-08-00124-f004){ref-type="fig"}a,b. Nonetheless, the subgroup analysis revealed an increase in the odds of congenital anomalies after smallpox vaccination (OR: 1.24; 95% CI 1.03--1.49) and a tendency towards an association with rubella vaccine, albeit with a very wide confidence interval (OR: 2.8; 95% CI 0.65--12.04).

No statistical heterogeneity was detected across studies for the overall effect of immunization on congenital defects (I^2^ = 0%), but there was substantial heterogeneity (I^2^ = 77.4%) between different vaccines when considering only first trimester immunization (*p* = 0·01 for subgroup differences, [Figure 4](#vaccines-08-00124-f004){ref-type="fig"}B). Quality of evidence was rated as very low, due to serious risk of bias ([Table S4](#app1-vaccines-08-00124){ref-type="app"}) and suspicion of publication bias ([Figure S3](#app1-vaccines-08-00124){ref-type="app"}).

### 3.1.4. Preterm Birth {#sec3dot1dot4-vaccines-08-00124}

Five studies were pooled in the meta-analysis for preterm birth, including two on smallpox, two on rubella vaccine, and one on OPV. No association was found between vaccination and prematurity (pooled OR: 0.99; 95% CI 0.90--1.08) overall and for each type of vaccine ([Figure S4](#app1-vaccines-08-00124){ref-type="app"}). No statistical heterogeneity was detected across studies (I^2^ = 0%), but there was moderate heterogeneity between subgroups (I^2^ = 42·7%). Quality of evidence was rated as very low as a result of serious risk of bias ([Table S5](#app1-vaccines-08-00124){ref-type="app"}).

### 3.1.5. Neonatal Death {#sec3dot1dot5-vaccines-08-00124}

Three studies on smallpox vaccine, one on rubella, and one on OPV contributed to the meta-analysis of neonatal death, showing no association with vaccination (pooled OR: 1.06; 95% CI 0.68--1.65), as depicted in [Figure S5](#app1-vaccines-08-00124){ref-type="app"}. No heterogeneity between estimates of effect was observed (I^2^ = 0%). Quality of evidence was rated as very low due to serious risk of bias ([Table S6](#app1-vaccines-08-00124){ref-type="app"}) and imprecision.

### 3.1.6. Sensitivity Analysis Excluding Studies at Critical Risk of Bias {#sec3dot1dot6-vaccines-08-00124}

Sensitivity analysis excluding four out of nine studies at critical risk of bias for the outcome of miscarriage revealed no association with vaccination (pooled OR: 0.97, 95% CI 0.86--1.09), consistent with the findings of the analysis including all studies. In the case of miscarriage after first trimester vaccination, all studies were at critical risk of bias and thus sensitivity analysis could not be conducted. For the rest of outcomes there were no studies at critical risk of bias.

3.2. Uncontrolled Cohorts {#sec3dot2-vaccines-08-00124}
-------------------------

Additionally, twenty-three uncontrolled cohorts \[[@B8-vaccines-08-00124],[@B10-vaccines-08-00124],[@B11-vaccines-08-00124],[@B12-vaccines-08-00124],[@B13-vaccines-08-00124],[@B22-vaccines-08-00124],[@B32-vaccines-08-00124],[@B38-vaccines-08-00124],[@B39-vaccines-08-00124],[@B40-vaccines-08-00124],[@B41-vaccines-08-00124],[@B42-vaccines-08-00124],[@B43-vaccines-08-00124],[@B44-vaccines-08-00124],[@B45-vaccines-08-00124],[@B46-vaccines-08-00124],[@B47-vaccines-08-00124],[@B48-vaccines-08-00124],[@B49-vaccines-08-00124],[@B50-vaccines-08-00124],[@B51-vaccines-08-00124],[@B52-vaccines-08-00124],[@B53-vaccines-08-00124],[@B54-vaccines-08-00124],[@B55-vaccines-08-00124],[@B56-vaccines-08-00124],[@B57-vaccines-08-00124],[@B58-vaccines-08-00124],[@B59-vaccines-08-00124],[@B60-vaccines-08-00124],[@B61-vaccines-08-00124]\] describing pregnancy outcomes after maternal vaccination were retrieved in the literature search. No cases of fetal vaccinia were found among 643 women vaccinated against smallpox \[[@B8-vaccines-08-00124],[@B58-vaccines-08-00124],[@B59-vaccines-08-00124]\], and rates of adverse pregnancy outcomes were within expected limits, except for a high frequency of stillbirth among those vaccinated in the first trimester \[[@B59-vaccines-08-00124]\] ([Table S7](#app1-vaccines-08-00124){ref-type="app"}).

Two controlled and twelve uncontrolled studies reported on the prevalence of CRS after maternal immunization \[[@B10-vaccines-08-00124],[@B11-vaccines-08-00124],[@B12-vaccines-08-00124],[@B13-vaccines-08-00124],[@B22-vaccines-08-00124],[@B32-vaccines-08-00124],[@B38-vaccines-08-00124],[@B39-vaccines-08-00124],[@B40-vaccines-08-00124],[@B41-vaccines-08-00124],[@B42-vaccines-08-00124],[@B43-vaccines-08-00124],[@B60-vaccines-08-00124],[@B61-vaccines-08-00124]\], as shown in [Table S8](#app1-vaccines-08-00124){ref-type="app"}. No cases were detected among 3918 infants, including 2303 born to women susceptible to rubella before vaccination. The upper bound of the 95% CI for the risk of CRS is 0.09% for all infants, and 0.16% for those born to susceptible women. These cohorts included participants receiving the Cendehill, HPV-77 and RA 27/3 viral strains, which might differ in their fetotropic potential \[[@B10-vaccines-08-00124]\].

No signs of unexpected adverse pregnancy outcomes were found in four uncontrolled cohorts of YF vaccine \[[@B16-vaccines-08-00124],[@B17-vaccines-08-00124],[@B62-vaccines-08-00124],[@B63-vaccines-08-00124],[@B64-vaccines-08-00124]\], except for an increase in minor dysmorphisms in a Brazilian cohort, which was probably explained by detection bias \[[@B62-vaccines-08-00124]\]. Only one case of probable intrauterine infection was detected among 422 infants tested for YF virus IgM ([Table S9](#app1-vaccines-08-00124){ref-type="app"}).

4. Discussion {#sec4-vaccines-08-00124}
=============

According to the author´s knowledge, this is the first systematic review on the safety of the administration of LAV during pregnancy. Available evidence comes mainly from cohorts of women vaccinated against smallpox and, to a lesser extent, from observational studies regarding rubella, OPV, YF, and dengue vaccines. With the exception of smallpox vaccine, maternal immunization with these other vaccines shows no evidence of impact on pregnancy outcomes, but available evidence is of very poor quality.

Smallpox vaccine is the only LAV clearly implicated in adverse pregnancy outcomes, given the documented cases of fetal vaccinia, but, according to the available evidence, the risk of this severe complication appears to be low. In the present review, an increase in the odds of birth defects was detected and an association between vaccination in the first trimester and miscarriage was also apparent. However, the studies evaluating this outcome were at critical risk of bias because women were identified at prenatal clinics or hospitals, and early pregnancy losses were likely to be missed, which could have decreased the effect estimate. Furthermore, some studies included all vaccinated women, while others assessed only those considered as "successfully vaccinated", i.e., subjects who developed a cutaneous reaction. The proportion of women who underwent primary vaccination as opposed to revaccination during pregnancy varied widely between studies, and preexisting immunity could result in different responses to smallpox vaccine (see [Table S7](#app1-vaccines-08-00124){ref-type="app"}).

The largest studies included in this review were two population-based cohorts, comprising nearly 30,000 women, exploring the safety of OPV in the context of mass vaccination campaigns and showed no increased risk of adverse pregnancy outcomes \[[@B27-vaccines-08-00124],[@B35-vaccines-08-00124]\]. In neither of these studies was exposure to vaccination determined at the individual level. However, mass campaign coverage was very high in both cases, increasing the confidence in their findings.

Despite the clear teratogenic action of wild-type rubella virus and the evidence of intrauterine infection in infants of women vaccinated during pregnancy, no cases of CRS have been documented in large cohorts of women inadvertently vaccinated during pregnancy or before conception in diverse settings and with different vaccine strains, which might have different fetotropic and teratogenic potential \[[@B10-vaccines-08-00124]\]. Maternal immunization with rubella vaccine does not appear to increase the risk of adverse pregnancy outcomes according to the available evidence from populations of women with varying degrees of previous immunity to rubella. However, the diversity of methods used to ascertain susceptibility and congenital infection, including hemagglutination-inhibition, IgM and IgG assays, IgG avidity tests, and viral isolation, could result in variable diagnostic accuracy.

Even though a total absence of risk cannot be proven, the likelihood of CRS is less than one per 1000 exposed pregnancies, according to available evidence \[[@B10-vaccines-08-00124],[@B11-vaccines-08-00124],[@B12-vaccines-08-00124],[@B13-vaccines-08-00124],[@B22-vaccines-08-00124],[@B32-vaccines-08-00124],[@B38-vaccines-08-00124],[@B39-vaccines-08-00124],[@B40-vaccines-08-00124],[@B41-vaccines-08-00124],[@B42-vaccines-08-00124],[@B60-vaccines-08-00124],[@B61-vaccines-08-00124]\]. Therefore, women inadvertently vaccinated during pregnancy should be reassured and therapeutic abortion would not be justified on the basis of a teratogenic potential of the vaccine.

The evidence regarding other LAV is even more scarce. In the case of YF vaccine, the only controlled study suggested an increased odds of miscarriage among vaccinated women, but the evidence for the association was weak. The mass vaccination campaign that provided the setting for this study was conducted after a dengue outbreak where organophosphate insecticides had also been used for vector control. Although reported exposure to organophosphates was similar between groups, measurement was imprecise, and residual confounding cannot be ruled out.

Other pregnancy outcomes after YF vaccination have been described only in uncontrolled studies. The largest of these cohorts followed 441 women inadvertently vaccinated in a mass campaign in Brazil \[[@B16-vaccines-08-00124],[@B62-vaccines-08-00124]\]; the frequency of stillbirths (0.7%) and preterm birth (7.8%) were similar or lower than regional rates as reported by the authors. Major birth defects were found in 3.3% of 304 newborns. Minor dysmorphisms were detected in 62 infants, a frequency greater than expected, but this was attributed to evaluation bias. IgM antibodies were undetectable in blood samples from 341 infants, but antibody persistence was detected in one of 37 children assessed after two years of age, raising the possibility of intrauterine infection.

The only study analyzing the safety of maternal immunization with dengue vaccine suggested a possible increase in the frequency of stillbirths \[[@B20-vaccines-08-00124]\], but there were only two events in the exposed group, both in adolescent mothers. This association, however, should be furthered explored.

No controlled studies fulfilling the inclusion criteria were found for the live-attenuated influenza vaccine (LAIV). Similarly, no studies on varicella-zoster virus (VZV) vaccine fulfilled inclusion criteria, but data on 893 women accidentally vaccinated during or shortly before conception is available from the Merck/CDC Pregnancy Registry \[[@B65-vaccines-08-00124],[@B66-vaccines-08-00124]\]. The prevalence of congenital anomalies (2.1%) was similar to that reported in the U.S. with no specific pattern of birth defects \[[@B67-vaccines-08-00124]\]. No cases of congenital varicella syndrome were detected among 810 infants.

The live-attenuated viral vectored vaccine against Ebola (rVSV-ZEBOV) is currently being administered to pregnant women as part of the ring vaccination strategy in Democratic Republic of Congo \[[@B68-vaccines-08-00124]\]. This will provide an opportunity to evaluate pregnancy outcomes to better inform decision-making in future outbreak scenarios.

Although the results presented in this manuscript are mostly reassuring, there are several limitations which preclude drawing final conclusions regarding the safety of maternal immunization with LAV. Besides the observational nature of the available evidence, most studies did not follow participants from the time of vaccination, leading to incomplete ascertainment of early pregnancy loses, which might include cases of congenital infection and malformations. Variable diagnostic criteria, ancillary methods and follow-up for ascertainment of birth defects can result in varying degrees of underreporting. The heterogeneity in study designs, settings, definitions and data collection methods leads to challenges in the comparison of different studies. On the other hand, the wide variety of countries and settings increases the generalizability to different populations. Furthermore, each LAV might have a different effect on pregnancy outcomes, which might be obscured by obtaining pooled effects. However, this was addressed by subgroup analyses which revealed an increased odds of miscarriage and congenital anomalies only after smallpox vaccination.

All but one of the included studies were considered at serious risk of bias due to confounding for all outcomes, since most of them did not measure potential confounding factors or did not control for them. Only the studies by Nishioka and Ryan provided an effect estimate adjusted for confounding \[[@B33-vaccines-08-00124],[@B36-vaccines-08-00124]\]. However, confounding domains were not measured validly in the first case, and some important confounders were not controlled for in the second. Bar-Oz et al. controlled for confounding by matching, but no information was provided on the methods used to measure these potential confounders \[[@B22-vaccines-08-00124]\].

Four out of nine studies were considered at critical risk of selection bias for the outcome of spontaneous abortion \[[@B24-vaccines-08-00124],[@B25-vaccines-08-00124],[@B30-vaccines-08-00124],[@B31-vaccines-08-00124]\], because participants were selected among women attending participating hospitals or clinics, thus missing those receiving care in different facilities and miscarriages occurring before onset of prenatal care.

The findings from this literature review cannot be directly extended to other LAV given the variable teratogenic potential of different vaccines. The use of modern technologies, such as viral vectored vaccines and novel adjuvants, might also modify the safety profile of live vaccines available in the near future. Furthermore, the power to detect a modest increase in the frequency of specific types of malformations is low, so the association of maternal vaccination with birth defects cannot be ruled out.

The development of new LAV that may target women of childbearing age, such as the viral vectored candidates for the prevention of Zika \[[@B69-vaccines-08-00124],[@B70-vaccines-08-00124]\], and the use of the existing ones in mass vaccination campaigns or in response to outbreaks will need to be coupled with enhanced surveillance of pregnant women and their infants, as well as standardized case definitions to better characterize the impact of vaccination on the mother-offspring dyad \[[@B71-vaccines-08-00124]\]. Additionally, more accurate baseline information on maternal and fetal outcomes in low and middle income countries (LMIC) is desirable to make comparisons with appropriate local rates \[[@B71-vaccines-08-00124]\].

Furthermore, other factors need to be taken into account when considering maternal immunization, including implementation challenges and the need for integration with existing prenatal care services, as well as the potential interference of maternal antibodies with the development of infant humoral immune responses to vaccines in the first few months of life. This interference has been observed for several vaccines but its clinical significance is still uncertain and might differ depending on the specific antigen \[[@B72-vaccines-08-00124],[@B73-vaccines-08-00124]\].

In summary, the risk of adverse pregnancy outcomes after maternal immunization with LAV appears to be small. This information can support decision-makers in the planning of vaccination campaigns that target women in the reproductive age, and may provide reassurance to healthcare workers taking care of women inadvertently immunized with LAV during pregnancy.

Our findings may also inform pressing decisions regarding vaccination of pregnant women during outbreaks. In this setting, benefits might exceed potential harms when the disease manifestations are severe for pregnant women and/or their offspring and the probability of exposure is high, as is the case with Ebola and Lassa Fever \[[@B74-vaccines-08-00124],[@B75-vaccines-08-00124]\].

Inclusion of pregnant women in vaccine trials under conditions of enhanced safety monitoring and appropriate follow-up of mothers and infants has the potential to expand the benefits of immunization to these populations. The views of pregnant women themselves need to be taken into account in research design and policy making. Qualitative research on vaccine confidence \[[@B18-vaccines-08-00124],[@B76-vaccines-08-00124]\] and willingness to participate in clinical trials, conducted in different settings and geographic locations, can help improve acceptance. We believe that pregnant women ought to be protected through research, not from research, in order to move forward in the promotion of health equity.
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###### 

Click here for additional data file.

A.L.-G. designed and undertook the literature review, extracted, analyzed and interpreted the data, wrote the paper and produced the figures; D.B.-S. extracted, analyzed and interpreted the data, reviewed the first draft and the final manuscript; A.J. provided substantial input for the design of the literature review, statistical analysis, and interpretation of the data, and reviewed the manuscript; B.K. conceived the idea for the review, provided substantial input for the design of the literature review, statistical analysis, and interpretation of the data, reviewed the all drafts and the final manuscript. All authors have read and agreed to the published version of the manuscript.

This research received no external funding.

The authors declare no conflict of interest.

Findings of the included studies reporting on pregnancy outcomes are summarized below, grouped by vaccine.

Appendix A.1. Smallpox Vaccine {#secAdot1-vaccines-08-00124}
==============================

Three prospective and four retrospective cohorts, as well as one case control study fulfilled the inclusion criteria. All were conducted between the 1940s and 1960s, except for one more recent cohort published in 2008.

Bellows et al. (1949) conducted a prospective cohort of 720 women who presented to antepartum clinics before the fourth month of pregnancy and who were vaccinated against smallpox during a mass campaign in New York, and 173 unvaccinated controls \[[@B23-vaccines-08-00124]\]. Among those less than 5 months pregnant at the moment of the vaccination campaign, 15 out of 428 (3.5%) exposed women and 4 out of 103 (3.9%) control women experienced miscarriage (OR: 0.90; 95% CI 0.29--2.77). Stillbirths occurred in 23 of 705 (3.3%) pregnancies that reached the fifth month in the exposed group, compared to 4 out of 169 (2.4%) in the control group (OR 1.39; 95% CI 0.47--4.08). Birth defects were documented in 3.3% and 2.4% of births (OR: 1.39, 95% CI 0.47--4.08), and neonatal deaths in 1.6% and 0.6% in the vaccinated and control groups respectively (OR: 2.69; 95% CI 0.34--21).

In another study carried out in New York, Greenberg et al. (1949) retrospectively studied 4172 infants born to mothers vaccinated in the first trimester of pregnancy and 2186 controls identified in the same hospitals and time period \[[@B26-vaccines-08-00124]\], and found no evidence of increased risk of major malformations among exposed newborns (0.7% versus 0.6%, OR: 1.25; 95% CI 0.65--2.40).

In a retrospective cohort in Cape Town, Abramowitz (1957) described the pregnancy outcomes of 1121 women vaccinated in the first 20 weeks of pregnancy and 201 unvaccinated women \[[@B21-vaccines-08-00124]\], finding no evidence of increased risk of stillbirth (1.9% versus 1.5%, OR: 1.26; 95% CI 0.37--4.26) or neonatal death (1.4% versus 1.5%, OR: 0.90; 95% CI 0.26--3.13). Twenty-four (2.1%) exposed and three (1.5%) unexposed infants were diagnosed with a congenital malformation (OR: 1.44; 95% CI 0.43--4.84).

Similarly, no evidence of increased risk of adverse pregnancy outcomes was found by Liebeschuetz (1964) in another retrospective cohort that included 157 vaccinated and 1657 unvaccinated or unsuccessfully vaccinated (no reaction at injection site) women attending a maternity hospital during a 6-month period after a mass vaccination campaign in London \[[@B30-vaccines-08-00124]\]. The majority of exposed women received the vaccine in the first trimester of pregnancy. The proportion of miscarriage (5.1% versus 4.5%, OR: 1.15; 95% CI 0.54--2.43) and stillbirth (2% versus 1.3%, OR: 1.53; 95% CI 0.45--5.19) was similar between exposed and unexposed women. Birth defects were diagnosed in 3 out of 149 births in the vaccine group and 22 of 1583 births in the control group (OR 1.46; 95% CI 0.43--4.93). No cases of fetal vaccinia were diagnosed among all live or stillborn infants.

Bourke and Whitty (1964) studied 112 women exposed to smallpox vaccine during pregnancy and 448 unexposed mothers attending antenatal clinics in four hospitals in Dublin \[[@B24-vaccines-08-00124]\]. The proportion of spontaneous abortion was the same in both groups (OR 1.0; 95% CI 0.11--9.04). Stillbirth was more common among exposed women (3.6% versus 1.3%) but the confidence interval of the odds ratio was compatible with no evidence for an association (OR 2.7; 95% CI 0.77--9.29). Similarly, congenital anomalies were detected more frequently in the vaccine group (3 of 113 births) in comparison with the control group (3 of 449 births) but the estimate of effect had a wide confidence interval including unity (OR 4.05; 95% CI 0.81--20.36). Two of the three mothers of malformed infants in the exposed group received the vaccine late in pregnancy (23 and 27 weeks) making a causal link unlikely. The frequency of neonatal deaths was 0.9% in both groups.

The pregnancy outcomes of 1522 women successfully vaccinated against smallpox at any stage of pregnancy during a mass campaign in Iran were prospectively described by Naderi (1975) and compared to 2014 unvaccinated women attending the same clinics during the following year \[[@B31-vaccines-08-00124]\]. All exposed women had received the smallpox vaccine in the past. Eighteen pregnancies in the exposed group and twenty-one in the control group ended in miscarriage (OR: 1.14; 95% CI 0.60--2.14). There were 23 stillbirths among vaccinated women and forty-eight among controls (OR: 0.63; 95% 0.38--1.04). The proportion of infants with malformations was similar between groups (1.4% versus 1.2%, OR: 1.17, 95% CI 0.66--2.08) but it was higher in the vaccine group when only those exposed in the first trimester were taken into account (3.5% versus 1.2%, OR: 2.90; 95% CI 1.24--6.79). With regards to specific defects, an increased risk for club foot was detected among infants exposed in the first trimester in comparison to the unexposed group (1.5% versus 0.25%, OR: 6.06; 95% CI 1.44--25.57). No cases of fetal vaccinia were detected in this cohort.

In a more recent study, Ryan et al. (2008) analyzed a cohort of infants born to active-duty military women using data from the U.S. Department of Defense Databases \[[@B36-vaccines-08-00124]\]. Birth defects were diagnosed in 40 of 882 infants exposed to smallpox vaccine during gestation and in 867 of 23,685 infants born to unvaccinated mothers (OR: 1.25; 95% CI 0.77--1.40). Estimates of effect were similar when considering only those exposed in the first trimester of pregnancy (OR: 1.24; 95% CI 0.85--1.81). These authors did not find an increased risk of club foot in infants of vaccinated mothers. The prevalence of preterm birth was similar between groups (7.5% versus 7.0%, OR: 1.07; 95% CI 0.83--1.38).

In the case control study by Saxen et al. (1968), 835 stillbirths and 642 newborns with congenital anomalies notified to the National Board of Health in Finland were compared to 1477 infants born next after the cases in the same district \[[@B37-vaccines-08-00124]\]. Birth defects were not significantly associated to vaccination during pregnancy or shortly before conception (OR: 1.18, 95% CI 0.88--1.57) or to vaccination during the first trimester (OR: 1.05; 95% CI 0.64--1.74). The odds of exposure to smallpox vaccine were lower among stillbirths in comparison to controls (OR: 0.71; 95% CI 0.52--0.96).

Appendix A.2. Rubella Vaccine {#secAdot2-vaccines-08-00124}
=============================

Two prospective and one retrospective cohorts evaluated pregnancy outcomes after exposure to rubella vaccine, with or without measles component. The rubella strain received by participants was RA 27/3 in two of the studies, and is not reported in the other one.

A retrospective cohort conducted by Ebbin et al. (1973) in Los Angeles County included 60 women inadvertently vaccinated during pregnancy or less than 3 months before conception and 47 controls matched for age, race, parity, sex of the infant and private/non-private hospital status \[[@B25-vaccines-08-00124]\]. No association was found between vaccination and miscarriage, with three cases documented in each group (OR: 0.77; 95% CI 0.15--4.01). Fourteen pregnancies in the exposed group were interrupted and rubella virus was isolated in two cases from products of conception. One of these isolates was characterized as wild-type and the other as attenuated rubella virus, although molecular methods were not yet available for confirmation. No virus was isolated in cultures of pharyngeal and rectal swabs taken from 34 exposed infants.

Bar-Oz et al. (2004) prospectively followed 94 women who called a telephonic counselling service for pregnant and lactating women in Toronto after being vaccinated against rubella within three months before or after estimated conception, and 95 controls counselled at similar gestational ages for non-teratogenic exposures \[[@B22-vaccines-08-00124]\]. No increased prevalence of miscarriage was found among vaccinated mothers as compared to controls (6.4% versus 8.4%, OR: 0.74; 95% CI 0.25--2.3) but seven pregnancies were interrupted due to fear of teratogenicity of rubella vaccine. No stillbirths were documented and congenital anomalies were diagnosed in three newborns in each group, showing no association with vaccination (3.7% versus 3.4%, OR: 1.08; 95% CI 0.21--5.5). There were no cases of congenital rubella syndrome among 81 exposed newborns.

A prospective cohort conducted by Namaei et al. (2008) included 106 women vaccinated within three months before or after conception during a mass campaign in Iran, and 40 unexposed controls \[[@B32-vaccines-08-00124]\]. Women with a history of previous rubella infection or vaccination were excluded from the study. One pregnancy in the exposed group (0.9%) and none in the control group ended in stillbirth. The prevalence of prematurity was 7.5% among exposed newborns and 7.1% among the unexposed. Birth defects were detected in 2 of 108 infants in the vaccine group and in none of the controls. No evidence of congenital infection was found on the basis of serological essays performed in all livebirths, and none of the children exhibited signs of CRS.

Appendix A.3. Oral Poliovirus Vaccine {#secAdot3-vaccines-08-00124}
=====================================

Pregnancy outcomes after OPV vaccination have been assessed in two population-based studies. Ornoy et al. (1993) conducted a historically-controlled study of women attending hospitals in West Jerusalem and the Tel Hashomer hospital who were pregnant at the time of a mass vaccination campaign, and a control group of pregnant women presenting at the participating hospitals during the same period in the previous year \[[@B34-vaccines-08-00124],[@B35-vaccines-08-00124]\]. The number of miscarriages was examined in relation to the reported annual livebirths and no difference was found in the prevalence between the two groups (OR: 0.96; 95% CI 0.85--1.09). With regards to birth defects, 243 were detected among 15,696 livebirths in the exposed cohort and 204 among 15,201 livebirths in the controls (OR: 1.14; 95% CI 0.95--1.38). Likewise, the prevalence of LBW was similar in the two groups (OR: 1.04; 95% CI 0.95--1.14).

After a mass vaccination campaign in Finland, Harjulehto et al. (1994) described the outcomes of 9508 live and stillborns in the Greater Helsinki region, born to women who were pregnant at the time of the vaccination campaign, comparing them to 12,126 births reported in the previous and following year in the same region \[[@B27-vaccines-08-00124],[@B28-vaccines-08-00124],[@B29-vaccines-08-00124]\]. No evidence of increased frequency of stillbirth (OR: 1.18; 95% CI 0.80--1.73), prematurity (OR: 0.93; 95% CI 0.84--1.04), neonatal death (OR: 1.01; 95% CI 0.61--1.68) or birth defects (OR: 0.9; 95% CI 0.75--1.08) was detected.

Appendix A.4. Yellow Fever Vaccine {#secAdot4-vaccines-08-00124}
==================================

With regards to YF vaccine, a single case control study in the setting of a mass vaccination campaign in Brazil fulfilled inclusion criteria. Nishioka et al. (1998) analyzed 39 women presenting for miscarriage at a university hospital and 74 women who attended the antenatal clinic at the same institution \[[@B33-vaccines-08-00124]\]. After adjusting for several confounders, the odds of exposure among cases was twice as that of controls, but the evidence of an association between miscarriage and vaccination was weak (OR: 2.29; 95% CI: 0.65--8.03, *p* = 0.20).

Appendix A.5. Dengue Vaccine {#secAdot5-vaccines-08-00124}
============================

The safety of dengue vaccine during pregnancy was analyzed in one industry-funded study consisting of a secondary analysis of data from clinical trials of the chimeric tetravalent dengue vaccine (CYD-TDV). Skipetrova et al. (2018) gathered information on 58 women inadvertently vaccinated during pregnancy or shortly before conception and 550 women either vaccinated outside of this "risk period" or participating in the placebo arm \[[@B20-vaccines-08-00124]\]. Seven percent of pregnancies ended in miscarriage in both groups; stillbirth was more frequent among the exposed participants (2/52 versus 4/499) although confidence interval crossed one (OR: 4.95; 95% CI 0.88--27.7). No congenital anomalies were diagnosed among 46 livebirths in the exposed group.

![Flowchart showing the study selection process for the qualitative and quantitative synthesis.](vaccines-08-00124-g001){#vaccines-08-00124-f001}

![Meta-analysis of the association between maternal immunization and miscarriage. Forest plots showing the effect of vaccination during pregnancy on the odds of miscarriage in all trimesters (**a**) and in the first trimester (**b**), subgrouped by vaccine.](vaccines-08-00124-g002){#vaccines-08-00124-f002}

![Meta-analysis of the association between maternal immunization and stillbirth. Forest plot showing the effect of immunization during pregnancy on the odds of stillbirth, subgrouped by vaccine.](vaccines-08-00124-g003){#vaccines-08-00124-f003}

![Meta-analysis of the association of maternal immunization with congenital anomalies. Forest plots showing the effect of immunization during pregnancy on the odds of congenital anomalies in all trimesters (**a**) and in the first trimester (**b**), subgrouped by vaccine.](vaccines-08-00124-g004){#vaccines-08-00124-f004}
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###### 

Characteristics of included studies.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                                                                    Location                                   Study Design                                         Exposure                                                                                                    Participants                                                                                                                        Exposure in 1st Trimester                                  Previous Immunity                                                                Control Group                                                                                                                                        Measured Outcomes
  ------------------------------------------------------------------------------------------------------------------------ ------------------------------------------ ---------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Abramowitz et al. (1957) \[[@B21-vaccines-08-00124]\]                                                                    Cape Town, South Africa                    Retrospective cohort                                 Smallpox vaccine before 20 weeks gestation                                                                  1121 vaccinated women (510 with successful vaccination \*)                                                                          NR                                                         NR                                                                               201 women not vaccinated during pregnancy                                                                                                            Stillbirth, birth defects, neonatal death.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcome definitions not reported

  Bar-Oz et al. (2004) \[[@B22-vaccines-08-00124]\]                                                                        Toronto, Canada                            Prospective cohort                                   Rubella (RA 27/3) vaccination ≤3 months before/after conception                                             94 women counselled about safety of rubella vaccination during pregnancy through a telephone service                                38 women                                                   NR                                                                               95 women counselled at similar gestational ages for non-teratogenic exposures, not vaccinated during pregnancy                                       Miscarriage, birth defects, congenital rubella syndrome, neonatal death. Outcomes reported by mother and physician ≥6 months after expected DOB

  Bellows et al. (1949) \[[@B23-vaccines-08-00124]\]                                                                       New York, U.S.                             Prospective cohort                                   Smallpox vaccination in pregnancy during a mass vaccination campaign                                        720 vaccinated women (571 successful vaccination \*) ≤4 months pregnant at admission to antenatal clinic                            247 women                                                  210/720 with accelerated reaction, suggestive of partial immunity                173 women admitted to the same antenatal clinics before 4 months gestation, not vaccinated during pregnancy                                          Miscarriage (before 5 months), stillbirth (after 5 months), birth defects (physical exam, fundoscopy, X-ray, follow-up for 12 months), neonatal death

  Bourke et al. (1964) \[[@B24-vaccines-08-00124]\]                                                                        Dublin, Ireland                            Prospective cohort                                   Successful smallpox vaccination \* at any stage of pregnancy                                                112 vaccinated women attending antenatal clinics in 4 hospitals that account for \>80% of births in Dublin                          54 women                                                   NR                                                                               448 women attending the antenatal clinics on the same day (4 adjacent charts), not vaccinated during pregnancy                                       Miscarriage, stillbirth, birth defects (including stillbirths), neonatal death.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcome ascertained from medical records. Definitions not reported

  Ebbin et al. (1973) \[[@B25-vaccines-08-00124]\]                                                                         Los Angeles County, U.S.                   Retrospective cohort                                 Rubella vaccination during pregnancy or within 3 months before conception                                   60 vaccinated women admitted to 7 participating hospitals or referred from private physicians                                       27 women                                                   9/60 previously susceptible, rest unknown                                        47 controls from hospital or private practice, matched for age, race, parity, sex of the infant, and private/non-private hospital status             Miscarriage, congenital infection (viral isolation in products of conception from abortion cases, or in pharyngeal and rectal swabs from live born infants)

  Greenberg et al. (1949) \[[@B26-vaccines-08-00124]\]                                                                     New York City, U.S.                        Retrospective cohort                                 Smallpox vaccination in 1st trimester of pregnancy during a mass campaign                                   4172 † infants born to vaccinated women in participating hospitals and health stations                                              4172 infants                                               NR                                                                               2186 infants born to non-vaccinated women in the same period, identified in participating hospitals and health stations                              Birth defects (excluding club foot, hydrocele, inguinal hernia and haemagiomas), LBW

  Harjulehto et al. (1993, 1994 and 1995) \[[@B27-vaccines-08-00124],[@B28-vaccines-08-00124],[@B29-vaccines-08-00124]\]   Greater Helsinki Region, Finland           Retrospective cohort (population-based)              OPV vaccination during mass campaign; exposure not determined at the individual level                       9508 ‡ births in the 3 hospitals that serve the region, born of women pregnant during the mass vaccination campaign                 2984 § births                                              Most women likely immune (IPV included in national schedule)                     12,126 live and stillbirths reported in the same hospitals from July to December 1984 and 1986                                                       Stillbirth (after 22 weeks EGA), prematurity, SGA, birth defects (BPA criteria, including autopsies), neonatal death (in the first 7 days of life)

  Liebeschuetz et al. (1964) \[[@B30-vaccines-08-00124]\]                                                                  London, UK                                 Retrospective cohort                                 Successful smallpox vaccination \* in pregnancy during a mass campaign                                      157 vaccinated women attending a maternity hospital during a 6-month period after mass campaign                                     131 women                                                  105/157 had received smallpox vaccine in the past                                1657 women attending the hospital during the same period who were not vaccinated or "unsuccessfully" vaccinated\*                                    Miscarriage, stillbirth, birth defects, fetal vaccinia. Outcome definitions not reported

  Naderi et al. (1975) \[[@B31-vaccines-08-00124]\]                                                                        Shiraz, Iran                               Prospective cohort                                   Successful smallpox vaccination \* in pregnancy during mass campaign                                        1542 infants of 1522 women attending university hospital clinics within 10 months after campaign                                    211 infants                                                All exposed women received smallpox vaccine in the past                          2045 infants of 2014 women not vaccinated during pregnancy and attending the same clinics during the following year                                  Miscarriage, stillbirth, prematurity, birth defects, clubfoot. Outcome definitions not reported

  Namaei et al. (2008) \[[@B32-vaccines-08-00124]\]                                                                        Birjand, Iran                              Prospective cohort                                   Rubella vaccine ≤3 months before/after conception, during a mass campaign                                   106 vaccinated women receiving antenatal care and delivering at a university hospital                                               71 women                                                   Women with previous infection or vaccination were excluded                       40 women not vaccinated during pregnancy. No details of recruitment provided                                                                         Stillbirth, prematurity, congenital infection (serology in cord or infant blood), congenital rubella syndrome (CDC's clinical criteria)

  Nishioka et al. (1998) \[[@B33-vaccines-08-00124]\]                                                                      Uberlandia, Brazil                         Case control                                         Yellow fever (17D) vaccination in pregnancy during a mass campaign §                                        CASES: 39 women attended for miscarriage at university hospital, with LMP ≥15 days before mass campaign                             NR                                                         NR                                                                               74 women living in the same city who attended the antenatal clinic at the university hospital                                                        Miscarriage (pregnancy loss before 28 weeks EGA)

  Ornoy et al. (1990 and 1993) \[[@B34-vaccines-08-00124],[@B35-vaccines-08-00124]\]                                       Israel                                     Historically-controlled cohort (population-based)    OPV vaccination during a mass campaign with 90% coverage; exposure not determined at the individual level   Women attending hospitals in West Jerusalem within 4 months of campaign (miscarriage) or ≤12 months after (birth defects, LBW) ‡\   NR                                                         Most women likely immune (poliovirus vaccine in national schedule since 1950s)   Women attending the included hospitals during the same period in the previous year, who were not vaccinated during pregnancy\                        Miscarriage (in relation to the number of annual births), birth defects (as proportion of annual live births), LBW (\<2500 grs birthweight). Outcomes obtained from hospital records
                                                                                                                                                                                                                                                                                                                                       N = 20,926 annual births                                                                                                                                                                                                                                                        N = 20,143 annual births                                                                                                                             

  Ryan et al. (2008) \[[@B36-vaccines-08-00124]\]                                                                          U.S.                                       Retrospective cohort. (Dept. of Defense databases)   Smallpox vaccination at any stage of pregnancy                                                              882 infants born during 2003-2004 to active-duty military women vaccinated inadvertently during pregnancy                           672 women                                                  NR, but probably not previous immunity (routine vaccination stopped in 1972)     23,685 infants born to military women not vaccinated against smallpox; 6853 infants born to active-duty women vaccinated before or after pregnancy   Prematurity (birth before 37 weeks EGA), birth defects (NBDPN definitions used, records up to 12 months of age reviewed). Outcomes defined using ICD-9-CM codes

  Saxen et al. (1968) \[[@B37-vaccines-08-00124]\]                                                                         Finland                                    Case control                                         Smallpox vaccination before or during pregnancy in the context of a country-wide campaign                   CASES 835 stillbirths and 642 infants with birth defects notified to the National Board of Health                                   NR                                                         73% of mothers in study group and 77% in control group previously vaccinated     1477 infants born next after stillbirth/malformed infants in the same district                                                                       Stillbirth, birth defects\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcome definitions not reported

  Skipetrova et al. (2018) \[[@B20-vaccines-08-00124]\]                                                                    Several countries (mostly Latin America)   Secondary analysis of data from clinical trials      Dengue (CYD-TDV) vaccination during pregnancy or \<30 days before LMP ("risk period")                       58 women inadvertently vaccinated during the "risk period" in CYD-TDV clinical trials                                               Most women vaccinated before or shortly after conception   NR                                                                               341 pregnant women vaccinated outside the "risk period", 30 received placebo during "risk period", 179 received placebo outside the "risk period"    Miscarriage (pregnancy loss before 20 weeks EGA), stillbirth (fetal death after 20 weeks EGA)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR = Not reported, NA = Not applicable, DOB = Date of birth, LBW = Low birth weight, EGA = Estimated gestational age, SGA = Small for gestational age, SD = Standard deviation, IPV = Inactivated poliovirus, CDC = Centers for Disease Control and Prevention, LMP = Last menstrual period, BPA = British Pediatric Association, NBDPN = National Birth Defects Prevention Network. \* Successful vaccination against smallpox implies development of a vesicle or pustule at the inoculation site. † N = 4238 in exposed group and 2214 in control group for assessment of LBW (longer follow-up to include all viable infants whose mothers were \<3 months pregnant at vaccination). ‡ Exposure status (vaccination during pregnancy) was not determined at the individual level. § Mass campaign after dengue outbreak with use of organophosphate fogging.
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###### 

Summary of findings.

  --------------------------------------------------------------------------------------------------- ------------------------------ -------------------------------------- ------------------------------------- -----------------------------------------------------------------------------------------------
  **Vaccination during Pregnancy Compared with No Vaccination.**                                                                                                                                                  

  **Patient or population:** Pregnant women and their fetuses/infants.\                                                                                                                                           
  **Intervention:** Administration of live vaccines during pregnancy or shortly before conception.\                                                                                                               
  **Comparison:** No exposure to live vaccines during pregnancy or shortly before conception.                                                                                                                     

  **Outcomes**                                                                                        **Relative Effect (95% CI)**   **Number of Participants (Studies)**   **Quality of the Evidence (GRADE)**   **Comments**

  Miscarriage                                                                                         OR 0·98 (0.87 to 1.10)         17,763 (9 studies)                     Very low                              Includes data on smallpox (4 studies), rubella (2), OPV (1), dengue (1), and YF (1) vaccines.

  Stillbirth                                                                                          OR 1·04 (0.74 to 1.48)         32,701 (9 studies)                     Very low                              Includes data on smallpox (6 studies), rubella (1), OPV (1), and dengue (1) vaccines.

  Congenital anomalies                                                                                OR 1.09 (0.98 to 1.21)         93,751 (12 studies)                    Very low                              Includes data on smallpox (8 studies), rubella (2), and OPV (2) vaccines.

  Preterm birth                                                                                       OR 0.99 (0.90 to 1.08)         49,995 (5 studies)                     Very low                              Includes data on smallpox (2 studies), rubella (2,) and OPV (1) vaccines.

  Neonatal death                                                                                      OR 1.06 (0.68 to 1.65)         24,499 (5 studies)                     Very low                              Includes data on smallpox (3 studies), rubella (1), and OPV (1) vaccines.

  Miscarriage after 1st trimester vaccination                                                         OR 2.66\|(0.73 to 9.64)        2832 (3 studies)                       Very low                              Includes data on smallpox (1 study) and rubella (1) vaccines.
  --------------------------------------------------------------------------------------------------- ------------------------------ -------------------------------------- ------------------------------------- -----------------------------------------------------------------------------------------------

GRADE Working Group grades of evidence. High quality: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.
